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Abstract
Tamoxifen, an anti-estrogen agent that can suppress breast cancer, has been reported to increase endometrium-related adverse events.
There are no guidelines for screening tamoxifen-treated patients for endometrial disease. We analyzed nationwide claims data related to
endometrial diseases to investigate patterns of endometrial disease in breast cancer patients who underwent hormonal treatment.
We sourced claims data from the Health Insurance Review and Assessment Service in South Korea. Patients who made their ﬁrst
claim for an anti-hormonal agent between January 1, 2010 and December 31, 2012 were enrolled retrospectively. We analyzed
patient characteristics and all claims related to endometrial disease, stratiﬁed by prescribed hormonal agents.
Among a total of 32,496 enrolled patients, 19,603 used tamoxifen only and 10,101 were treated with an aromatase inhibitor (AI)
alone. Endometrial events occurred in 15.4% (3028/19603) of the tamoxifen-only patients and 2.0% (201/10101) of the AI-only
group. In patients diagnosed with breast cancer at the age of 50 or older, the hazard ratio (HR) of endometrial malignancy in the
tamoxifen-only group compared to the AI-only group was 4.13 (95% CI 1.404–12.159, P = .010). The HR of curettage in the
tamoxifen-only group was 31.0 (95% CI 19.668–48.831, P<.001).
The occurrence of endometrial events among tamoxifen-treated breast cancer patients was higher than in patients treated with
only AI, similar to previous studies. However, the HR of curettage was uniquely high, despite its invasiveness. Guidelines for screening
endometrial disease and improvements of healthcare policy are required to appropriately manage high-risk patients.
Abbreviations: AI = aromatase inhibitor, D&C = dilation and curettage, HR = hazard ratio, ICD = International Classiﬁcation of
Disease, IRB = institutional review board, PAP = Papanicolaou.
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Early detection and advanced adjuvant treatment have improved
survival in breast cancer patients. Research interest has, therefore,
turned to strategies for improving quality of life among breast
cancer survivors.[1–3] The health of breast cancer patients isEditor: Akif Enes Arikan.
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1affected by the treatment processes they undergo and related side
effects. Adjuvant hormonal therapy requires a long treatment
period, which can extend for up to 10 years and can signiﬁcantly
impact the health of breast cancer survivors.[4,5] The NSABP B-35,
a large-scale randomized controlled trial in a breast cancer cohort,
reported side effects of tamoxifen and anastrozole with quality of
life impacts.[6] Such side effects can reduce adherence to adjuvant
treatment.[7] The side effects of tamoxifen have a wide spectrum,
ranging from abnormal vaginal bleeding to increased risk of
endometrial cancer.[8–13] In addition, tamoxifen therapy for breast
cancer has been reported to cause a higher rate of endometrial
disease and to be associated with poorer prognosis in cases of
endometrial cancer in numerous previous studies.[8,12]
The utilization of gynecologic services has increased in
tamoxifen-treated breast cancer patients, and it has become
apparent that switching from tamoxifen to anastrozole signiﬁ-
cantly reduces the need for a second hysteroscopy and/or dilation
and curettage (D&C), further indicating that there are correlations
between tamoxifen and endometrial disease.[9,14] However,
routine transvaginal ultrasonography of patients receiving tamox-
ifen is not recommended because of the inconsistencies in imaging
results and histology, and the invasiveness of the procedure.[15–17]
There are no deﬁnitive guidelines for managing breast cancer
patients showing no adverse symptoms of tamoxifen other than
initial screening and regular Papanicolaou (PAP) smear exams,
which are both commonly recommended.[18–20]
There is also no clear consensus as to when and how tamoxifen
regimens should be changed or even discontinued when there are
suspected symptoms or signs of adverse effects. Alternative drugs to
Lee et al. Medicine (2019) 98:2 Medicinetamoxifen are also limited. The absence of screening guidelines for
endometrial disease in patients treated with tamoxifen can also lead
to inappropriate investigations. Accurate gynecologic diagnosis and
appropriate investigation are therefore important for breast cancer
patients treated with tamoxifen in comparison with patients who
receive other treatments, especially during early periods of therapy.
Since a patientmay be treated atmore than 1 hospital, data from
medical institutions of various sizes should be included in order to
accurately investigate adverse events due to drugs. In South Korea,
national insurance claims data cover all medical institutions. We
used these data in the present study to investigate the early
occurrence of endometrium-related clinical events in breast cancer
patients treated with anti-hormonal agents.[21] Notably, the
greatest increases in standardized incidence ratios (SIR) of
endometrial cancer in hormone receptor-positive breast cancer
havebeen found inAsian-Americanand Indian-Americanpatients,
but no nationwide studies have been conducted in East Asian
countries.[22] We address this shortfall in the current analysis by
analyzing nationwide claims data regarding endometrial exams,
procedures, and diagnosis in Korean breast cancer patients.
2. Methods
2.1. Data sources and patient selection
We screened claims data for breast cancer patients provided by the
Health Insurance Review and Assessment Service (HIRA) of KoreaFigure 1. Flow chart o
2for the period from January 1, 2009 to December 31, 2014 to
include in our present study cohort. These data indicated that a total
of 48,137,244 claims were classiﬁed and analyzed for 128,492
patientswithmain diagnoses of breast cancer. Breast cancer patients
whomade their ﬁrst claims for hormonal treatment from January 1,
2010 to December 31, 2012 were included in the analysis. We
extracted patient identiﬁcation numbers, patient age, sex, the start
date of the claim, the end date for the claim, main diagnosis codes
(International Classiﬁcation of Disease [ICD]-10), sub-diagnosis
codes (also in ICD-10), claimed agent/exam/procedure codes, and
additional data frame such as detailed prescription information. To
screen for newly diagnosed breast cancer cases during the survey
period that was eligible for our analysis, we identiﬁed patients who
started anti-hormonal treatmentwithin 1-year of breast surgery and
had a 1-year wash-out period.
To evaluate the causal effects of the anti-hormonal agents in
our study subjects, we excluded patients with total coverage of
less than 1-year for these drugs; for whom the insurance claim
was not properly processed (i.e., follow-up loss) within 1 year of
ﬁrst making the claim for this treatment; who made a claim for
only 1 hormonal agent prescription; or who made any claim
related to an endometrial disease at around the same time as the
ﬁrst anti-hormonal agent claim (Fig. 1).We then collected data on
the included patients including age at breast cancer diagnosis and
claims data for treatment with anti-hormonal agents and against
any therapies for endometrial-related events.f patient selection.
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We deﬁned endometrial events using both diagnostic and exam/
procedural claims data. The codes representing a main diagnosis
of abnormal uterine and vaginal bleeding (N93), endometrial
hyperplasia (N85) and malignant neoplasm of the uterus (C54,
C55, D07, including carcinoma in situ of the endometrium) were
taken to indicate an endometrium-related diagnosis. The codes
that represented different clinical tests and procedures were
sorted into 3 categories:(1)Ta
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AI=exam such as an endometrial biopsy (other than curettage or
PAP smear) or pelvic ultrasonography;
D&C; and(2)
(3) hysterectomy.Patients with a history of endometrial events within 1-year of
the ﬁrst anti-hormonal agent claim were excluded to remove
cases of underlying or coincident endometrial disease. Only
endometrial events that occurred after at least 1-year exposure to
an anti-hormonal agent were considered valid for analysis. We
adopted this approach to more precisely assess the occurrence of
endometrial disease due to anti-hormonal therapy.2.3. Statistical analysis
The study patients were classiﬁed into 3 treatment groups:
tamoxifen-only, aromatase inhibitor (AI)-only, and treatment
with both agents (both-group). The tamoxifen-only and AI-only
patients had no drug changes or switching. The both-group
included patients treated with these agents in either order. The
patient data included suspected age at breast cancer diagnosis,
chemotherapy regimens, treatment adherence during the 3-year
study period, in-hospital deaths, and endometrial events. These
were evaluated according to the treatment group. Factors related
to anti-hormonal agent coverage were presented as the number of
patients for whom the total agent coverage was less than 3 years.
Since the indications for AI therapy are limited after
menopause, we conducted further analyses of patients in our
cohort older than 50 years. In addition, adverse events related to
tamoxifen are reported to be correlated with age.[6,14,23]
Differences in endometrial events between the 3 study groups
were analyzed using the chi-square test. Survival analysis ofble 1
ient characteristics and endometrial events.
racteristics
Tamoxifen only
N=19,603 (60.32%)
ian age at breast cancer diagnosis, Range 46 (18∼90)
ge under 50 14,351
ge range of 50∼59 3,580
0 and above 1,672
vant chemotherapy 642 (3.28)
ication coverage < 3yr 6,424 (32.77)
spital death 149 (0.76)
of patients with any claims related
endometrial events, %
3,028 (15.4)
bnormal vaginal bleeding 1,366
ndometrial hyperplasia 731
ndometrial malignancy 28
ndometrial exam 826
ilation and curettage 1,258
ysterectomy 305
aromatase Inhibitor.
3event-free survival outcomes was investigated in the 3 study
groups using log-rank tests with a Kaplan–Meier curves and age-
adjusted Cox regression analysis. All reported P values were 2-
sided, and P values less than .05 were considered signiﬁcant. R
software version 3.2 (http://cran.r-project.org/) was used for all
statistical analyses.2.4. Ethics
This study was approved by the institutional review board (IRB)
of Asan Medical Center, Korea (IRB no. 2017–0654). The
requirement for informed consent was waived by our IRB, as this
study involved routinely collected medical data that were
anonymously managed at all stages, including during data
cleaning and statistical analysis.3. Results
We enrolled a total of 32,496 breast cancer patients treated with
an anti-hormonal agent and for whom 2-year wash-out was
performed. Of these cases, 19,603 patients (60.3%) had only
received tamoxifen and 10,101 (31.1%) were administered AI
alone (Table 1). More than 50% of the patients on tamoxifen
alone (14,351/19,603, 73.2%) were less than 50 years of age. Of
the total patient cohort, 4.3% (1413/32,496) also underwent
chemotherapy. During the study period, 33.8% (10,972/32,496)
of these patients received an anti-hormonal agent for less than 3
years and were also analyzed.
Among the total of 9306 endometrial events in 3582 of our
study patients, 84.1% (7825/9306) occurred in the tamoxifen-
only group, and 4.2% (392/9306) occurred in the AI-only group.
This compares with a rate of endometrial events in the total
cohort of 15.4% (3028/19,603) in the tamoxifen-only group and
2.0% (201/10,101) in the AI-only group. Among the claims with
endometrium-related main diagnoses, bleeding (3333 claims)
was the most frequent, followed by hyperplasia (2184 claims)
and malignancy (572 claims). Among claims made for tests and
procedures, curettage (1625 claims) was the most frequent
followed by exam (1193 claims) and hysterectomy (399 claims).
A total of 16,753 patients in the total cohort were diagnosed
with breast cancer when older than 50 (Table 2). Of these, 5252
patients (31.3%) were in the tamoxifen-only group, and 9559AI only
N=10,101 (31.08%)
Both
N=2,792 (8.59%)
Total
N=32,496
58 (37∼91) 53 (29∼96) 50 (18∼96)
542 850 15,743
5,043 1,187 9,810
4,516 755 6,943
588 (5.82) 183 (6.55) 1,413 (4.35)
3,654 (36.17) 894 (32.02) 10,972 (33.76)
141 (1.40) 155 (5.55) 445 (1.37)
201 (2.0) 353 (12.6) 3,582 (11.0)
112 134 1,612
23 88 842
7 7 42
50 106 982
22 137 1,417
27 67 399
Table 2
Endometrial events for patients diagnosed with breast cancer at the age of 50 and above.
Endometrial events
Tamoxifen only
N=5,252 (31.3%)
AI only
N=9,559 (57.1%)
Both
N=1,942 (11.6%)
Total
N=16,753
No. of claims (Number of patients)
Any events 1941 (719) 334 (181) 571 (201) 2846 (1101)
Tamoxifen only P<.001 P= .029
AI only P<.001
Abnormal vaginal bleeding 647 (312) 154 (99) 197 (90) 998 (501)
Tamoxifen only P<.001 P= .203
AI only P< .001
Endometrial hyperplasia 517 (199) 36 (22) 174 (55) 727 (276)
Tamoxifen only P<.001 P= .639
AI only P<.001
Endometrial malignancy 92 (11) 42 (5) 6 (1) 140 (17)
Tamoxifen only P= .088 P= .062
AI only P= .759
Endometrial exam 265 (210) 55 (46) 63 (50) 383 (306)
Tamoxifen only P<.001 P= .004
AI only P<.001
Dilation and curettage 355 (314) 22 (20) 107 (93) 484 (427)
Tamoxifen only P<.001 P= .081
AI only P<.001
Hysterectomy 65 (65) 25 (25) 24 (24) 114 (114)
Tamoxifen only P<.001 P= .995
AI only P<.001
AI= aromatase Inhibitor.
Lee et al. Medicine (2019) 98:2 Medicine(57.1%) were in the AI-only group. Of the 2864 claims made by
patients over 50 years of age, 68.2% (1941/2846) occurred in the
tamoxifen-only group and 11.7% (334/2846) in the AI-only
group. Endometrial event variables showed a signiﬁcantly higher
frequency in the tamoxifen-only group compared with the AI-
only group (P<.05). In the tamoxifen-only group, there were
more claims related to exams, malignancy, and D&C compared
to the both-group (P= .004, P= .062, P= .080). The both-group
claims data also indicated that all endometrial events except forFigure 2. Unadjusted Kaplan–Meier curves for (a) abnor
4malignancy (P= .759) had a signiﬁcantly higher occurrence
compared with the AI-only group (P<.001).
Log-rank tests and Kaplan–Meier curve analysis of event-
free survival following endometrial events in patients over 50
showed distinct differences between the 3 treatment groups
(Figs. 2–4). In all survival curves, the AI-only group showed
better event-free survival outcomes than the tamoxifen-only
group. However, claims associated with malignancy
showed no signiﬁcant difference between the AI-only groupmal vaginal bleeding and (b) endometrial hyperplasia.
Figure 3. Unadjusted Kaplan–Meier curves for (a) malignant neoplasm of endometrium and (b) exams to evaluate the endometrium.
Lee et al. Medicine (2019) 98:2 www.md-journal.comand both-group, and there was no signiﬁcant difference
between the both-group and tamoxifen-only group in the
curve for hysterectomy claims (Figs. 3 and 4). In age-adjusted
Cox regression analysis, the tamoxifen-only group showed a
hazard ratio (HR) of 7.62 (95% CI 6.459–9.004, P<.001)
for all endometrial events compared to the AI-only group,
(95% CI 19.668–48.831, P<.001) and 4.13 (95% CI 1.404–
12.159, P= .010) for malignancy. The HR for D&C in the
tamoxifen-only group, compared to the AI-only group was
30.78 (95% CI 19.668–48.831, P<.001).Figure 4. Unadjusted Kaplan–Meier curves for (a
54. Discussion
We found that early endometrial events are more frequent in
breast cancer patients treated with tamoxifen than in those
treated with other anti-hormonal therapies. The lower incidence
(15.4%) of endometrial events in the tamoxifen-only group
compared with rates reported in previous studies of 20% to 60%
may be due to the 2-year wash-out period before and after the day
of the ﬁrst anti-hormonal agent claim in our patient
series.[14,24,25] In all of the claims types in our current cohort) dilation and curettage and (b) hysterectomy.
Lee et al. Medicine (2019) 98:2 Medicineexcept for malignancy, the tamoxifen-treated group (tamoxifen-
only group and both-group) showed higher risk of endometrial
events than the AI-only group. In addition, D&C claims showed
the highest HR in the tamoxifen-only group (HR=30.78). The
HR of endometrial malignancy was signiﬁcantly higher only in
the tamoxifen-only treated patients in our series.
We found no differences in risk for malignancy between the AI-
only group and both-group (HR=0.97, 95% CI 0.113–8.348,
P= .978). Due to the study period, we adopted for patient
enrollment (from 1 January 2010 with data collection to
December 31, 2014), the duration of hormone treatment
coverage did not exceed 5 years in any of the patients we
analyzed. In the both-group patients, who had shorter periods of
tamoxifen exposure, our ﬁndings supported previous results
indicating that the prolonged use of tamoxifen increases the risk
of endometrial cancer.[8,12] Hence, more frequent gynecologic
investigations and more detection efforts should be considered in
tamoxifen-treated patients due to the increased risk of endome-
trial malignancy.
Our age-adjusted risk analysis and Kaplan–Meier curves
indicated that the risk of endometrial events increased with the
duration of tamoxifen exposure. This suggests that the need for
gynecological investigations in these patients has not been not
overestimated. However, with reference to the AI-only group, the
D&C claims showed a signiﬁcantly higher HR in the tamoxifen-
only group. This ﬁnding is likely to the dual functionality of D&C
as an investigation and treatment procedure. The rate of intra-
operative complications of non-obstetric D&C, such as uterine
perforation, false passage, severe hemorrhage, and vaginal/cervical
laceration, have been reported at 1.9%, which is similar to the
proportion of claims for D&C and to the number of patients with
endometrial malignancy in the tamoxifen-only group (28/1441,
1.9%).[15] Although latent complications such as infection or
adhesion can occur, adverse events arising from diagnostic D&C
have been reported at lower rates (1.4%).[26] However, we found
inour current analysis that theHRofD&Cclaimswas remarkably
higher than that for bleeding (5.9), hyperplasia (18.1), or
malignancy (4.1). In addition to less invasive investigations such
as transvaginal/pelvic USG, non-invasive exams such as magnetic
resonance imaging are viable methods of evaluating the endome-
trium.[27] However, these alternative procedures are not currently
covered by national health insurance in Korea.
Based on previous study ﬁndings that the risk of tamoxifen-
induced endometrial cancer is signiﬁcantly increased in older
patients, we conducted a chi-square test and survival analysis in
cases who had a diagnosis breast cancer at the age of 50 or older,
a group that comprised only 26.8% of the total tamoxifen-only
patients.[23] This is consistent with the high incidence of young
breast cancer patients reported in countries.[28] In our sub-
analysis of patients aged 50 and above, the proportion of cases
with an endometrial malignancy showed the smallest decrease
(11/28, remain 39.3% after age limitation), while the hysterec-
tomy claims showed the greatest decrease (65/305, remain
21.3%). This is presumably because a hysterectomy is performed
only once in a lifetime. In the sub-groups of patients over 50, the
percentage of patients with an endometrial malignancy who had
undergone a hysterectomy was 14.9% (17/114). This suggests
that most of the hysterectomies in this group had been performed
due to a benign disease of the endometrium. Similarly, the event-
free survival curves for hysterectomy between the tamoxifen-
treated and AI-only groups diverged at the early stage of
treatment. The survival curves for endometrial malignancy
showed a long latency period in our analysis.6The medication coverage index indicated that the majority of
the patients in our analysis complied with the anti-hormonal
treatment regimens within the 3-year study period. However,
prescription claims for anti-hormonal agents do not necessarily
indicate adherence. The adverse effects of anti-hormonal agents
are also known to cause non-adherence.[7] However, patients
who experience endometrial events may have continued taking
tamoxifen, as this is recommended to them when discussing
possible side effects. Further investigations are needed to evaluate
the level of adherence to tamoxifen and other anti-hormonal
regimens before and after the occurrence of an endometrial event.
Longer-term follow-up of tamoxifen-taking patients with
endometrial events is also needed.
Early recognition of the side effects of a drug facilitates the
consideration of treatment changes or even discontinuation.
Moreover, by considering the timing of an adverse event from the
beginning of a particular drug regimen, the appropriateness of
this intervention can be more adequately assessed. The gradual
increase in the number or intensity of follow-up assessments in
accordance with degree of tamoxifen exposure will enable a more
accurate assessment of whether the accumulated dose is the cause
of an adverse event.[29] The observation that risk increases with
the duration of tamoxifen suggests that side effects increase with
exposure to tamoxifen.
Some details of the patients included in the present study are
not included in claims data (e.g., weight and height, menopause
status, breast cancer stage and subtype, pathology results of
hysterectomy) and therefore could not be assessed. However, the
national claims data we used provided far more generic
information on the use of medications than the records of any
single institution. To enable early detection of adverse events
following hormone therapy, we focused on early endometrial
events in our study. Further evaluation studies that include real-
time and long-term research, such as risk prediction model
analysis of endometrial events, are needed.
The present study is the ﬁrst to use national data from an East
Asian country to analyze the occurrence of endometrial events in
breast cancer patients receiving anti-hormonal therapy. The use
of such data, rather than relying on subjective reporting of
symptoms by patients themselves, could provide a far more
reliable and useful guide for the use of these treatments. With the
lack of current screening guidelines for endometrial disease in
breast cancer patients receiving anti-hormonal therapy, proper
patient education is crucial. Our study approach and ﬁndings will
assist with the drafting of recommendations for evaluating
endometrial events, development of screening guidelines for
breast cancer patients with or without symptoms, and establish-
ment of health policies for breast cancer survivors with histories
of anti-hormone treatment.5. Conclusions
The early detection of any side effects from a medication is
important for determining the most appropriate treatment
direction. It is also necessary to identify patterns of side effects
that occur during a particular treatment. As found in previous
studies, the results of our current analysis indicate that patients
treated with tamoxifen have signiﬁcantly increased risk of
developing endometrial events. In the case of malignancy, the
only difference between AI-only treated patients and the
tamoxifen-only group was likely due to the latency period for
malignancy caused by tamoxifen exposure. The appropriateness
of using curettage and hysterectomy cannot be conﬁrmed by our
[11] Swerdlow AJ, Jones ME. and G. British Tamoxifen Second Cancer
Lee et al. Medicine (2019) 98:2 www.md-journal.compresent investigation and we did not include histology informa-
tion. However, it is clear that guidelines for the screening of
endometrial diseases and improvements in healthcare policy are
required for appropriate management of high-risk patients.
Additional research is thus needed to determine the long-term
effects of hormonal therapy, compliance with medication, and
the effectiveness of curettage and hysterectomy, including more
detailed information on breast cancer patients undergoing such
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